Kinsley Wang

Ms. Kinsley Wang


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2026 in Antibodies
Verified
Journal Article
Open access
PDF file
KWKinsley Wang
Kinsley Wang
KTKyle Taing
Kyle Taing
RHRobert Hsu
Robert Hsu
Background/Objectives: Small-cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy characterized by rapid proliferation, early metastasis, and near-universal relapse after initial therapy. While chemo-immunotherapy modestly improves first-line outcomes, survival after progression remains poor and highlights the urgent need for biomarker-directed strategies. Methods: A comprehensive literature search was conducted using major medical databases looking at key relevant studies on SCLC antibody studies. All authors reviewed the literature, assessed study quality, and interpreted the results from each study. Results: Recent advances in antibody–drug conjugates (ADCs) and T-cell engagers (TCEs) have transformed therapeutic development by targeting antigens selectively expressed on SCLC cells, enabling more precise and potentially durable tumor control. DLL3 has emerged as the most clinically relevant target to date, with the bispecific TCE tarlatamab demonstrating meaningful and durable response, manageable cytokine-release toxicity, and ultimately achieving accelerated FDA approval for previously treated extensive-stage SCLC. Concurrently, DLL3-directed ADCs have shown variable efficacy, underscoring the importance of payload selection, linker chemistry, and antigen density. Beyond DLL3, next-generation ADCs targeting TROP2, B7-H3, and SEZ6 have reported encouraging early-phase activity, including response rates exceeding those of existing second-line cytotoxic options, though myelosuppression, interstitial lung disease, and hepatic toxicity remain key considerations. Conclusions: Collectively, these emerging immunotherapies illustrate a shift toward antigen-specific targeting in a disease historically defined by limited therapeutic innovation. Continued optimization of antigen selection, payload and linker engineering, and biomarker-driven trial design will be critical for translating early promise into durable clinical benefit and reshaping the treatment landscape for SCLC.

23 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
JCJulia Cheng
Julia Cheng
KWKinsley Wang
Kinsley Wang
ZAZhaohui Liao Arter
Zhaohui Liao Arter
DBDavid Benjamin
David Benjamin
RHRobert Hsu
Robert Hsu
Lung cancer remains the leading cause of cancer-related death worldwide. Epidermal growth factor receptor (EGFR) mutations are among the most common oncogenic drivers in non-small cell lung cancer (NSCLC), with L858R point mutation or exon 19 deletions accounting for the majority of EGFR mutations. The development of EGFR-targeted therapies has significantly improved clinical outcomes and overall survival in patients harboring these classical activating mutations. However, EGFR exon 20 insertion mutations (Ex20ins) exhibit resistance to earlier-generation tyrosine kinase inhibitors (TKIs), including erlotinib, gefitinib, and afatinib, due to structural alterations that limit drug binding and reduce therapeutic efficacy. To address these challenges, novel EGFR-targeted TKIs and bispecific monoclonal antibodies have emerged as promising treatment strategies for patients with Ex20ins-mutated NSCLC. This review summarizes recent advances in targeted therapies for EGFR Ex20ins, highlighting treatments approved by the US Food and Drug Administration (FDA), including amivantamab and sunvozertinib, as well as emerging agents such as firmonertinib, zipalertinib, and becotarug.

29 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
RZRose Valerie Zach
Rose Valerie Zach
KWKinsley Wang
Kinsley Wang
RARebecca Avez
Rebecca Avez
ARAbraham Rubinov
Abraham Rubinov
TGTatyana Gadaev
Tatyana Gadaev
SLSalvatore Lettieri
Salvatore Lettieri
Unhoused individuals are three times more likely to sustain traumatic injuries than the general population, with approximately 40% experiencing head and facial trauma. Limited access to follow-up care can delay treatment and worsen outcomes. This study examined the incidence, fracture types, and outcomes of facial trauma in relation to housing status. A retrospective analysis was conducted using the National Trauma Data Bank (NTDB). Demographics, injury patterns, hospital course metrics, and discharge locations were compared between housed and unhoused patients. Statistical analyses included t-tests, Chi-squared tests, and regression models for length of stay (LOS) and discharge location. Unhoused patients were significantly older than housed (46.54 vs. 43.82 years, p< 0.001) with male predominance (70% vs 65% male, χ²=286.92, p< 0.001). Despite higher ICU admission rates (58.4% vs. 51.4%, p< 0.001), they had shorter hospital stays (6.95 vs. 10.60 days, p< 0.001) and were more likely to receive non-surgical management despite similar injury patterns. Insurance coverage was lower among unhoused individuals, who demonstrated a higher burden of comorbidities, including alcohol use, smoking, diabetes, hypertension, and mental/personality disorders. Multivariate analysis revealed that housing status remained a significant predictor of LOS and discharge location after controlling for demographics, insurance status, fracture type, and comorbidities (p< 0.01). Unhoused populations face significant disparities in facial trauma care. Future research should explore evidence-based strategies to improve outcomes, including immediate surgical intervention when feasible, as follow-up care remains a significant challenge for unhoused patients.

20 July 2026 in OTA International
Verified
Journal Article
Open access
KWKinsley Wang
Kinsley Wang
ASAngeli Sirilan
Angeli Sirilan
RZRose Valerie Zach
Rose Valerie Zach
AJAnnie Jia
Annie Jia
NANimit Agarwal
Nimit Agarwal
NDNiloofar Dehghan
Niloofar Dehghan
Objectives: To evaluate differences in clinical outcomes between housed and homeless older adults hospitalized for ground-level falls. Methods: Design: Retrospective cohort. Setting: A nationwide study in the United States using the National Trauma Data Bank (NTDB). Patients/Participants: The study identified 1136 homeless and 325,267 housed patients. Patients aged ≥50 years hospitalized for ground-level falls were identified using ICD-10 external cause codes. Housing status was defined through home residence variable. Intervention: None. Main Outcome Measurements: The primary outcomes were fracture rate and length of stay (LOS) ≥7 days; secondary outcomes included ICU admission, complications, injury pattern, in-hospital mortality, and discharge location. Results: Homeless patients were significantly younger (mean age 65.3 vs 74.6 years, P < 0.0001) and had lower fracture rates (51.2% vs 59.3%, P < 0.0001). Rates of femoral neck, femoral shaft/distal end, humeral, and distal radial fracture were significantly lower in the homeless population. Despite lower fracture rates, homeless individuals had worse outcomes: longer mean LOS (8.82 vs 6.63 days, P < 0.0001), higher rates of ICU admission (25.3% vs 19.8%, P < 0.0001), and complications (11.5% vs 6.3%, P < 0.0001). Homelessness was independently associated with prolonged LOS (odds ratio 1.55, 95% confidence intervals 1.37–1.76, P < 0.0001). Conclusions: Homeless patients had lower fracture rates, potentially reflecting differences in age. Despite sustaining fewer fractures, homelessness was independently associated with significantly worse outcomes, even after controlling for age, comorbidities, and injury severity. These findings highlight significant disparities driven by homelessness and underscore the need for integrated care models addressing both medical and social determinants of health. Level of Evidence: Level III.